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Stickeler: The principle of a dual blockade of the HER2 re-
ceptor pathway was my highlight. Even if most of these inno-
vative findings were already reported at the San Antonio 
Breast Cancer Symposium the evidence of the superiority is 
now striking and the procedure is becoming clinical practice.
Question 2: uPA/PAI1 vs. Oncotype DX vs. 
Endopredict etc. – What Is Your Preferred Concept 
to Differentiate in Intermediate-Risk Patients?
Liedtke: Since none of these tests has yet demonstrated 
 superiority this question is difficult to answer. In our depart-
ment, we are currently using particularly uPA/PAI-1 or Endo-
predict. However, I am convinced that recommending chemo-
therapy to a patient with intermediate-risk breast cancer 
should depend on both disease prognosis and prediction of 
response (to endocrine therapy). Therefore, I strongly sup-
port the ongoing ADAPT trial which stratifies patients to 
 either receive or not receive chemotherapy depending on 
their response to short-term endocrine therapy (measured 
by sequential measurement of KI-67). Patients should be 
strongly encouraged to participate in this trial if possible.
Rack: Oncotype DX has shown prognostic and predictive 
relevance in several retrospective analyses by different re-
search groups. An advantage is also that the test can be per-
formed on formalin-embedded tissue and is therefore avail-
able in most clinical settings. 
Schütz: Unfortunately there is no prospective trial avail-
able that has proven the predictive nature of any test for 
 modern systemic treatment. We have decided to use the pro-
liferation marker Ki67 to decide whether chemotherapy is 
necessary or not. Although there is still a lack of information 
we have used Oncotype DX a few times over the last years. 
Question 1: What Was Your Personal Highlight  
of ASCO 2013 in Breast Cancer?
Liedtke: Compared to previous meetings this year’s ASCO 
Annual Meeting did present with a number of interesting data 
rather than one particular highlight. These aspects comprise 
data regarding adjuvant therapy in HER2-positive breast 
 cancer, axillary staging, and optimization of adjuvant chemo- 
and endocrine therapy. Since axillary staging in general has 
recently been an issue of debate in both the adjuvant and the 
neoadjuvant setting, I was particularly interested to see the 
data regarding the AMAROS trial presented by Rutgers et 
al., demonstrating equal efficacy for axillary dissection and 
axillary radiation in patients with sentinel lymph node-posi-
tive breast cancer.
Rack: The aTTom trial confirming prolonged benefit from 
extended adjuvant tamoxifen treatment for 10 years after pri-
mary diagnosis was my personal highlight. 10 years of tamox-
ifen resulted in an improvement of 15% for breast cancer 
mortality compared to only 5 years of treatment.
Schütz: Two studies have shown us that our knowledge 
about classical medication in early breast cancer can still be 
optimized: in the GeparSixto trial presented by Gunter von 
Minckwitz the addition of carboplatin to an anthracycline/
taxane sequence improved pathological complete response 
(pCR) in triple negative breast cancer (TNBC) up to 60%. 
However, only 52% of the patients were able to take the 
planned 6 cycles, mostly due to toxicity. Furthermore, in 
 endocrine therapy the 10-year follow up of the aTTom trial 
was presented. With regard to the recently published ATLAS 
trial (Lancet, 2013) it was shown in more than 18,000 patients 
that 10 years of tamoxifen reduces recurrence rate as well as 
mortality over the following years. However, patients have to 
deal with a higher incidence of endometrial cancer.
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Stickeler: Since uPA/PA1 was evaluated in a truly prospec-
tive setting I prefer this test momentarily. However, the evi-
dence for Oncotype DX is strong since the data were gener-
ated in prospectively designed trials in a so-called retrospec-
tive-perspective manner. 
Question 3: Is There a Standard in Adjuvant 
Treatment of Triple Negative Breast Cancer?  
Are There Several?
Liedtke: Since chemotherapy is indicated in the majority of 
patients with TNBC at the time of diagnosis, a neoadjuvant 
approach is usually recommended. At this year’s ASCO, the 
German GeparSixto trial conducted by the German Breast 
Group (GBG) has demonstrated significant efficacy of a 
 taxane-anthracycline chemotherapy regimen in combination 
with weekly carboplatin particularly among patients with 
TNBC. Although a pCR rate of about 60% could be observed 
among patients with TNBC, the authors observed a signifi-
cant range of toxicities with 44% of patients experiencing at 
least 1 serious adverse event. Therefore, use of this regimen in 
clinical routine cannot yet be recommended. 
Rack: According to present guidelines, adjuvant chemo-
therapy should be performed irrespective of the molecular 
tumor subtype. However, the Gunter von Minckwitz pre-
sented promising data from the GeparSixto trial in the 
TNBC subgroup, showing an increase of pCR with a platinum 
based treatment. This could be a new option for TNBC. 
 However, the increased toxicity of this regimen with only 
60% of patients being able to complete chemotherapy has to 
be kept in mind.
Schütz: I don’t think that we can define one standard treat-
ment for TNBC. We try to personalize the systemic treatment 
by discussing every patient in our pretherapeutic tumor con-
ference. We try to treat all TNBC patients in the neoadjuvant 
setting to observe tumor regression. Therefore we mainly use 
the classical TAC regimen. However, if we find nodal involve-
ment after primary chemotherapy we discuss a post-neoadju-
vant systemic treatment, e.g. with carboplatin based chemo-
therapy, in this high-risk group.
Stickeler: So far there is no standard for TNBC. However, 
the treatment guidelines of the AGO suggest to stay within 
the published adjuvant treatment protocols. The data from 
the GeparSixto trial presented in Chicago support the hypo-
thesis that patients diagnosed with this clinical subtype will 
profit from the addition of carboplatin in the neoadjuvant 
 setting. These phase II data are promising but need further 
confirmation. 
Question 4: What Does Modern Radiotherapy  
Look Like Now and in the Next Years?
Liedtke: The efficacy of radiotherapy in enhancing locore-
gional control among patients with early breast cancer is well 
established. The results of the AMAROS trial suggest that in 
certain clinical scenarios (axillary) radiation provides an op-
tion to replace axillary dissection with equal efficacy but less 
toxicity. However, retrospective analyses suggest that both, 
risk of locoregional recurrence and efficacy of adjuvant radio-
therapy strongly depend on molecular subtypes. I believe that 
locoregional control through radiotherapy may eventually be 
decided on in an equally personalized fashion as we currently 
decide on adjuvant systemic therapy.
Rack: As efficacy and side effects are comparable, hypo-
fractionated radiotherapy regimens will probably be used 
more frequently in the future. Irradiation of the axilla might 
be an option in selected cases (AMAROS trial). Intraopera-
tive boost or intraoperative radiotherapy as only radiation 
treatment for low-risk patients is becoming a convenient al-
ternative for many patients.
Schütz: Over the next years we will observe a trend to-
wards taking back the extent of radiotherapy as it has 
 happened in the surgical treatment as well. Intraoperative 
 radiotherapy (IORT) as well as partial breast irradiation in 
defined subgroups may be as effective as whole breast 
irradiation. 
Stickeler: In my opinion hypofractionation will be the first 
step towards an innovative safe, less toxic, and faster irradia-
tion concept. 
Question 5: What Is the Greatest Innovation  
in the Treatment of Metastatic Breast Cancer?
Liedtke: To date the most interesting proof of concept 
in the treatment of metastatic breast cancer is to reverse 
 resistance against endocrine therapy and/or HER2-targeted 
agents through the use of molecularly targeted agents such 
as the mTOR inhibitor everolimus in the BOLERO-2 and 
BOLERO-3 clinical trials, respectively. These data show that 
molecular manipulation of cancer cells is possible and effec-
tive. However, this approach also poses several questions, 
such as at which disease stage (i.e. curative vs. metastatic) 
these agents should be used or whether to continue these sub-
stances upon diagnosis of disease progression. These ques-
tions will need to be answered soon and accordingly trials are 
currently ongoing.
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Rack: There was not much new in metastatic breast cancer. 
The BOLERO-3 trial was presented comparing daily everoli-
mus plus weekly trastuzumab and vinorelbine in trastuzumab-
resistant, advanced breast cancer. O’Regan could show a 
 statistically significant improvement of progession free sur-
vival from 5.78 to 7 months. However, the clinical benefit in 
view of HER2-targeted agents, i.e. dual blockade, and TDM-1 
is still unclear.
Schütz: We have made significant improvements in the 
 systemic therapy of metastatic breast cancer over the last 
years. However, over time most of the patients will experi-
ence a resistance against new therapies. Drugs which can 
modify that resistance like will become more and more impor-
tant in this setting. The mTOR-inhibitor everolimus is an 
 example for these new drugs as it may re-sensitize tumor cells 
for an endocrine therapy. Furthermore the combination of 
targeted therapies and ‘old school anticancer treatment’, such 
as TDM-1, is of special interest. This combination of an anti-
body (against HER2) and a cytotoxic molecule (emtansine) 
brings the toxic agent only inside those cells that expresses 
HER2 – a fascinating new way to treat HER2-positive breast 
cancer.
Stickeler: The development of highly effective concepts to 
overcome resistance to HER2-targeted drugs with the innova-
tive dual blockade as well as the specific delivery of cytotoxics 
by an antibody guided approach as well as the targeting of 
 endocrine resistance by new pathway inhibitors (e.g. mTOR 
inhibition) are great innovations. 
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